Cleared Traditional

K093976 - RAISIN PERSONAL MONITOR (FDA 510(k) Clearance)

Class II Cardiovascular device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K093976 · Proteus Biomedical, Inc. · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Mar 2010
Decision
91d
Days
Class 2
Risk

K093976 is an FDA 510(k) clearance for the RAISIN PERSONAL MONITOR. Classified as Transmitters And Receivers, Electrocardiograph, Telephone (product code DXH), Class II - Special Controls.

Submitted by Proteus Biomedical, Inc. (Redwood City, US). The FDA issued a Cleared decision on March 25, 2010 after a review of 91 days - within the typical 510(k) review window.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.2920 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Cardiovascular review framework, consistent with the majority of Class II 510(k) submissions.

View all Proteus Biomedical, Inc. devices

Submission Details

510(k) Number K093976 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 24, 2009
Decision Date March 25, 2010
Days to Decision 91 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
34d faster than avg
Panel avg: 125d · This submission: 91d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DXH Transmitters And Receivers, Electrocardiograph, Telephone
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.2920
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - DXH Transmitters And Receivers, Electrocardiograph, Telephone

All 296
Devices cleared under the same product code (DXH) and FDA review panel - the closest regulatory comparables to K093976.
PreemptiveAI Clinical SDK
K250233 · Measure Labs, Inc. (Dba Preemptiveai, Inc.) · Feb 2026
HeartBeam AIMIGo with 12-L ECG Synthesis Software System
K250258 · Heartbeam, Inc. · Dec 2025
MEMO Patch M (MPT-E08R-UNC01)
K243438 · Huinno Co., Ltd. · Dec 2025
Hexoskin Medical System (7100-00016)
K243981 · Carre Technologies, Inc. · Nov 2025
VitalSigns 1-Lead Holter (VSH101)
K243003 · VitalSigns Technology Co., Ltd. · Jun 2025